Progressive Supranuclear Palsy Clinical Trials

• WP1: Healthy controls

• Age between 18 and 90 years old (15 aged 18-50 years and 25 aged 50 90 years);

• Subject is judged to be in good health by the investigator on the basis of medical history, physical examination including vital signs and clinical laboratory tests;

• No history or evidence of current major neurological, internal or psychiatric disorder, based on the medical assessment as described hereabove and neuropsychological assessment;

• No evidence of cognitive impairment as assessed by a Montreal Cognitive Assessment (MoCA) score of 26 or higher at baseline;

• In subjects \< 60 years of age, a normal structural MRI scan as assessed by expert radiologist.

• In subjects \>= 60 years of age white matter hyperintensities corresponding to a WML (white matter lesion) score \<= 2 (of 3) on the Age-Related White Matter changes scale are acceptable;

• When older than 50 years of age, the volunteer is willing to undergo a p- tau217 blood sample.

• WP2: Dementia

• Patient has a clinical diagnosis of biomarker-proven prodromal AD

• WP3: ALS spectrum

• Subject must meet El Escorial Criteria (30) and Awaji-Shima criteria (31) for at least possible ALS;

• WP4: Movement disorders

• (all): Patient (or legal representative, when applicable) is able to understand the patient information form and give written informed consent.

• Parkinson´s disease (PD):

• Patient has clinically established PD based on the Movement Disorder Society (MDS) diagnostic criteria (32);

• Patient has an abnormal 18F-PE2I PET;

• No evidence of cognitive impairment as assessed by a Montreal Cognitive Assessment (MoCA) score of 26 or higher at baseline.

• Multiple system atrophy (MSA)

• Patient has clinically established or clinically probable MSA-P based on the

• Movement Disorder Society (MDS) diagnostic criteria (33);

• Patient has an abnormal 18F-PE2I PET.

• Progressive supranuclear palsy (PSP)

• Patient has an abnormal 18F-PE2I PET;

• Patient has clinically established probable PSP according to the latest MDS criteria

• Dementia with Lewy bodies (DLB)

• Patient has probable DLB by consensus criteria (cognitive impairment MoCA \< 26 + visual hallucinations and/or fluctuating alertness);

• Patient has an abnormal 18F-PE2I PET.

• Idiopathic REM sleep behavior disorder (iRBD)

• Patient has Polysomnography-confirmed iRBD;

• No evidence of cognitive impairment as assessed by a Montreal Cognitive Assessment (MoCA) score of 26 or higher at baseline;

• No clinical evidence of parkinsonism at baseline.

• WP5: Psychosis

• DSM 5 criteria for a non-affective schizophrenia spectrum psychotic disorder;

• Age between 18 and 55 years old for adult-onset psychosis, onset of psychosis (and age) above 60 years old for very late onset psychosis.